insights_auto
Miks on MVIR tõusnud? 5,77%?
Uurige põhjalikumaltchevron_right
MVIR:STO
Medivir AB
1,69 SEK
arrow_upward
+5,77%(+0,092) 1 p
2. okt, 17:29:51 GMT +2 · SEK
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse MVIR põhistatistika genereerimine…
Ava
1,71 SEK
Kõrge
1,78 SEK
Madal
1,67 SEK
Turu kapit.
1,06 mld
Keskm. maht
1,88 mln
Maht
2,72 mln
52 näd kõrgeim
2,88 SEK
52 näd madalaim
0,34 SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18 mln
Töötajate arv
6
Ava
1,71 SEK
Kõrge
1,78 SEK
Madal
1,67 SEK
Turu kapit.
1,06 mld
Keskm. maht
1,88 mln
Maht
2,72 mln
52 näd kõrgeim
2,88 SEK
52 näd madalaim
0,34 SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18 mln
Töötajate arv
6
Uudised
Veebiallikatest ja uudistepartneritelt
The Motley Fool
·
27 minuti eest
4 Stocks Delivered About Half of the S&P 500's Gain This Year
Investor's Business Daily
·
1 tunni eest
Dow Jones Futures: Nasdaq Hits High As Nvidia, SpaceX, Bloom Energy Flash Buy Signals. What To Do Now.
Business Wire
·
4 tunni eest
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Profiil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Teave üksuse Medivir AB kohta